(1) Both infections are transmitted in similar ways, mainly through blood or transfusion of blood products and other means. (2) The clinical manifestations are similar, but there are more cases of asymptomatic and jaundice free hepatitis C. Some patients are not easily detected, and liver function tests often show elevated single transaminases that do not decrease continuously or fluctuate repeatedly. (3) Both have the tendency to develop into chronic hepatitis and cirrhosis, the incidence of which is higher in hepatitis C than in hepatitis B. The risk of hepatitis C developing into primary hepatocellular carcinoma is greater. (4) Because of similar transmission routes, hepatitis C and hepatitis B can be overlapping infections, and overlapping infections have higher rates of severe hepatitis and death than individual infections, indicating that overlapping infections of hepatitis C and hepatitis B can exacerbate liver damage. (5) Hepatitis C may also be transmitted by sexual contact and mother-to-child transmission, but the incidence is not as high as that of hepatitis B. How to carry out follow-up monitoring of antiviral? (1) Pre-treatment monitoring program. Liver and kidney function, blood routine, thyroid function, blood glucose and urine routine should be tested before treatment. Blood count should be checked once a week in the first month after starting treatment, then once a month until 6 months, and then once every 3 months. (2) Biochemical tests. ALT should be checked every month during treatment and every 2 months for 6 months after the end of treatment. ALT should be rechecked regularly even if the patient fails to clear HCV. (3) Virological tests. HCV RNA should be measured at 3 months of treatment; HCV RNA should also be tested at the end of treatment and 6 months after the end of treatment. (4) Monitoring of adverse reactions. All patients should have their thyroid function tested every 6 months during treatment and every 3 to 6 months after the end of treatment, or monthly if abnormal thyroid function was present before treatment. For elderly patients, electrocardiogram and cardiac function determination should be done before treatment. Mental status should be evaluated regularly, especially in patients who exhibit significant depression and suicidal tendencies, and the medication should be discontinued and closely guarded.